Metastatic Melanoma with Jason Luke, MD and Jeffrey Weber, MD, PhD: Case 1 - Episode 10
If required, what would your second-line therapy be?
In a patient who has a BRAF mutation and initiates dabrafenib/trametinib as frontline therapy to target that mutation, second-line therapy includes multiple options and really becomes clinically dependent what’s going on with this patient at the time? Unfortunately, we see that a high percentage of patients who initiate targeted therapy towards BRAF subsequently develop brain metastases as their first site of progression. In that context, then radiation is a likely component to your treatment, and we have to think about whether or not steroids are involved. And that then decides if you can use immunotherapy eventually, etc.
CASE: Metastatic Melanoma
Charles, a 62-year-old Caucasian landscaper, presented to his primary care physician with fatigue, dyspnea upon exertion, and a nonproductive cough that has lasted for 6 to 8 weeks. .
Treatment was initiated with the combination of BRAF and MEK inhibitors.